ProfileGDS5678 / 1426433_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 44% 48% 49% 47% 45% 39% 43% 36% 41% 48% 45% 46% 63% 46% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 13.0680344
GSM967853U87-EV human glioblastoma xenograft - Control 23.1375948
GSM967854U87-EV human glioblastoma xenograft - Control 33.173349
GSM967855U87-EV human glioblastoma xenograft - Control 43.0396247
GSM967856U87-EV human glioblastoma xenograft - Control 53.0032145
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 12.9715839
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 23.0570843
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 32.7970636
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 42.9138241
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 13.1115248
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 23.0543645
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 33.0495646
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 43.7597363
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 53.0617446